Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis,[1] under development by Anthos Therapeutics.

Mechanism of action

It is anti-factor XI antibody. The hope behind its developoment is that factor XI plays a bigger role in thrombosis (via the intrinsic/contact activation pathway) than hemostasis, so targeting it might reduce clotting risks without a corresponding increase in bleeding.[1] It has, indeed, shown overwhelming reduction in bleeding as compared to a direct oral anticoagulant (rivaroxaban) in patients with atrial fibrillation and a moderate-to-high risk of stroke.[2] Data is insufficient for drawing a conclusion on whether it increases or decreases stroke events as compared to rivaroxaban.[3]

See also

References

  1. ^ a b Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, et al. (August 2021). "Abelacimab for Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (7): 609–617. doi:10.1056/NEJMoa2105872. PMID 34297496. S2CID 236198598.
  2. ^ "Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)". Business Wire. 18 September 2023.
  3. ^ Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, et al. (January 2025). "Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation". The New England Journal of Medicine. 392 (4): 361–371. doi:10.1056/NEJMoa2406674. PMID 39842011.
Allikas: https://en.wikipedia.org/wiki/Abelacimab
No tags for this post.